Skip to content

Compassion Focused Therapy for Distressing Experiences

A Case Series Study of Compassion Focused Therapy for Distressing Experiences

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02733575
Enrollment
9
Registered
2016-04-11
Start date
2015-09-30
Completion date
2019-01-08
Last updated
2019-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychosis

Brief summary

This study aims to develop and test the feasibility of a new therapy called Compassion Focused Therapy (CFT) for psychosis. This therapy helps people with psychosis manage distressing experiences by building internal feelings of safeness and affiliation, and by providing contexts, practices and insights that facilitate the development of compassion to self and others. The focus is on helping people feel safe in relation to their experiences and their social worlds. CFT is a promising new approach that has been successfully provided for people with a range of mental health difficulties. It is also firmly based in the most up-to-date knowledge and science about how the mind works (both normally and under stress). 9 participants will be recruited from NHS psychological therapies services for people with psychosis in South London and Maudsley (SLAM) NHS Foundation Trust. Following a short baseline period they will receive up to 26 weekly sessions (about 6 months) of CFT with a clinical psychologist, and will provide interview and questionnaire research data at five different points during the study. At these assessment points, data will be gathered on participants' experiences, mood, perceptions of their position in the social world, and heart rate variability. The initial therapy protocol has been developed by psychologists with expertise in CFT, alongside people with lived experience of hearing voices and having distressing beliefs. However, it will continue to be developed and evolve as the study progresses, and as more is learnt (e.g. from the service-user participants) about applying the model in this population. At the end of this study, the aim is to have all the information needed to run a randomised controlled trial of this therapy.

Interventions

Up to 26 sessions of Compassion Focused Therapy

Sponsors

King's College London
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Over 18 years old * Psychosis related diagnosis (F20-39) * Distressing positive symptoms of psychosis. Each participant will have been routinely screened with PSYRATS at their service entry assessment. On PSYRATS, at least one positive symptom (i.e. hallucination or delusion) will be present, and distress will be evidenced by an associated intensity score of 2 or above * Willing to engage in psychological therapy * Sufficient command of English language * Able to provide informed consent

Exclusion criteria

* Currently engaged in CBT, or have completed a 12+ session course of CBT within the last 3 years. If recruitment is under target, this will be relaxed to 12+ session course of CBT (Cognitive Behavioural Therapy) within the last 6 months * Currently engaged with another treatment study (e.g. medicine or therapy)

Design outcomes

Primary

MeasureTime frame
Attrition rate measured by number dropping out of therapy6 months

Secondary

MeasureTime frameDescription
Psychotic symptoms measured by PSYRATSOver 6 months of therapy, and 6-8 weeks post-therapyMeasured by PSYRATS (Psychotic Symptom Rating Scales)
Depression and anxiety symptoms measured by DASS-21Over 6 months of therapy, and 6-8 weeks post-therapyMeasured by DASS-21 (Depression, Anxiety and Stress Scale)
Subjective wellbeing, symptoms, functioning, and risk/harm measured by COREOver 6 months of therapy, and 6-8 weeks post-therapyMeasured by CORE (Clinical Outcomes in Routine Evaluation)
Dissociative experiences measured by DES-IIOver 6 months of therapy, and 6-8 weeks post-therapyMeasured by DES-II (Dissociative Experiences Scale)

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026